Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 3 of 3
Full-Text Articles in Medicine and Health Sciences
Treatment Options For Parkinson’S Disease, Sara Russ
Treatment Options For Parkinson’S Disease, Sara Russ
The Science Journal of the Lander College of Arts and Sciences
The following is an excerpt from this article: Parkinson’s disease was first described and named Paralysis Agitans in 1817 by British physician James Parkinson (Lieberman 2004). Later on, it took on its current name after Dr. Parkinson. Parkinson’s disease (PD) is a neurological disorder for which the cause is yet to be discovered. Like many other diseases, PD has numerous facets. Throughout all of its different stages, it presents with motor, as well as nonmotor, symptoms (Simuni et al. 2009). Though estimates of people affected by PD are constantly being made, it is difficult to determine a precise and accurate …
Imatinib Resistance In Philadelphia Chromosome-Positive Chronic Myeloid Leukemia, Rivky Kops
Imatinib Resistance In Philadelphia Chromosome-Positive Chronic Myeloid Leukemia, Rivky Kops
The Science Journal of the Lander College of Arts and Sciences
Chronic myeloid leukemia (CML) is a disorder of blood stem cells in bone marrow, which leads to a rapid production of white blood cells. Of the patients diagnosed with CML, 95% have the Philadelphia (Ph) chromosome, which means that chromosome 22 is smaller than regular (22 q-). Historically, the median survival time for chronic phase CML patients was four to five years, while the accelerated and blast (profusion of immature red blood cells in circulation) phases had a much shorter survival time. Recently, due to the revolutionary new drug imatinib, CML patients diagnosed early have a higher survival rate. Nevertheless, …
Quest For Vaccines To Treat Addiction, Rachel Florence
Quest For Vaccines To Treat Addiction, Rachel Florence
The Science Journal of the Lander College of Arts and Sciences
Drug addiction is a prime example of biochemical psychology. When people use drugs such as nicotine, they trigger dopamine receptors in the brain, causing a pleasurable sensation. People want to repeat the feeling and thus get addicted to the drug. With the development of a vaccine to treat addiction, researchers attempt to prevent drugs from crossing over the bloodbrain barrier and triggering the dopamine receptors. Experiments and clinical trials prove the efficacy of the nicotine vaccine. However, Phase III trials and additional research are necessary before the vaccine can be launched for public use.